Accessibility Menu
Mayne Pharma Group logo

Mayne Pharma Group(ASX) MYX

Market CapA$263.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-55%
5 Year-34%
1 Year-36%
1 Month+16%
A$3.24
-0.92%
-0.03Today
Mayne Pharma Group last closing stock price
MetricPriceDate
Last closeAUD 3.242026-08-13
Mayne Pharma Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.52%AUD 3.102026-08-06
1 month+15.71%AUD 2.802026-07-14
3 month+40.26%AUD 2.312026-05-15
Year to date+4.18%AUD 3.112025-12-31
1 year-35.71%AUD 5.042025-08-13
3 year-31.79%AUD 4.752023-08-14
5 year-34.19%AUD 4.922021-08-13
Since inception-54.73%AUD 7.222007-06-29

Mayne Pharma Group Financials at a Glance

Market Cap

A$263.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$820.64M

Net Income (TTM)

-A$212.46M

EPS (TTM)

-A$1.02

P/E Ratio

-3.16

Dividend

A$0.00

Beta (Volatility)

0.01 (Low)

Price

A$3.24

Volume

122,798

Open

A$3.27

Previous Close

A$3.24

Daily Range

A$3.20 - A$3.27

52-Week Range

A$2.04 - A$6.50

Estimated Earnings Date

Aug 27, 2026

MYX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mayne Pharma Group

Mayne Pharma Group Limited operates as a specialized pharmaceutical enterprise, focusing on the global production and distribution of both proprietary and generic medicinal products. The company serves diverse markets including Australia, New Zealand, North America, Europe, and Asia, with a strong emphasis on innovative oral drug delivery technologies.

Products and Services
  • Proprietary and generic pharmaceutical products
  • Comprehensive contract services including pharmaceutical development
  • Specialization in therapeutic areas like dermatology and women's health
Growth Outlook
  • Revenue of AUD 212 million in the latest quarter, showing strong market demand
  • Continued investment in R&D to enhance product offerings and innovation
  • Expansion into new markets expected to drive future revenue growth
Financial Highlights
  • Net income of AUD -14.9 million in the latest quarter, reflecting ongoing challenges
  • Gross profit margin of 50.4% indicates strong product profitability
  • Cash and cash equivalents of AUD 67.3 million provide liquidity for operations
Mayne Pharma Group Limited is positioned within the healthcare sector, specifically in drug manufacturing. The company has a diverse portfolio that includes both branded and generic products, catering to various therapeutic areas. Recent financial performance indicates a revenue increase, although net income remains negative, highlighting the need for continued operational improvements. The company's focus on research and development, along with its strategic market expansions, suggests potential for future growth. Investors may find interest in the company's innovative approaches and market reach, despite current financial challenges.
AI Generated • Jul 29, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

450

CEO

Shawn Patrick O'Brien

Website

www.maynepharma.com

Headquarters

Salisbury South, SA 5106, AU

MYX Financials

Key Financial Metrics (TTM)

Gross Margin

54.83%

Operating Margin

-11.15%

Net Income Margin

-20.44%

Return on Equity

-23.02%

Return on Capital

-5.73%

Return on Assets

-8.85%

Earnings Yield

-31.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$263.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

81.25M

Volume

122.80K

Avg. Volume

271.24K

Financials (TTM)

Gross Profit

A$467.07M

Operating Income

-A$59.01M

EBITDA

-A$32.35M

Operating Cash Flow

A$22.83M

Capital Expenditure

-A$18.36M

Free Cash Flow

A$4.46M

Cash & ST Invst.

A$67.35M

Total Debt

A$44.62M

Mayne Pharma Group Performance Analysis

Mayne Pharma Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 157,147,000N/A
20232023-06-30AUD 183,586,00016.8%
20242024-06-30AUD 388,399,000111.6%
20252025-06-30AUD 408,095,0005.1%
Mayne Pharma Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-306.7%
Q22024-12-316.3%
Q42025-06-30-8.5%
Q22025-12-318.7%
Mayne Pharma Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -3.42N/A
20232023-06-30AUD -3.677.3%
20242024-06-30AUD -2.19-40.3%
20252025-06-30AUD -1.19-45.8%
Mayne Pharma Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-50.6%
Q22024-12-3180.9%
Q42025-06-30-256.0%
Q22025-12-3179.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$212.07M

+12.8%

Gross Profit

A$106.80M

+43.7%

Gross Margin

50.36%

N/A

Market Cap

A$263.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$536.12K

N/A

Employees

491

N/A

Net Income

-A$14.94M

+78.8%

EBITDA

A$5.81M

+115.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$67.35M

-56.5%

Total Debt

A$44.62M

+22.0%

Accounts Receivable

A$192.59M

-3.2%

Inventory

A$47.50M

-48.3%

Long Term Debt

A$4.31M

-87.0%

Short Term Debt

A$40.31M

+481.2%

Return on Assets

-8.85%

N/A

Return on Invested Capital

-6.65%

N/A

Free Cash Flow

-A$9.37M

+77.4%

Operating Cash Flow

-A$8.06M

+68.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MVF.AXMonash IVF Group Limited
A$0.70+0.72%
OCC.AXOrthocell Limited
A$0.79-0.63%
DXB.AXDimerix Limited
A$0.30+1.72%
PSQ.AXPacific Smiles Group Limited
A$2.18+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.62+0.07%
ONDSOndas
$8.93-0.09%
SMCISuper Micro Computer
$39.34+0.05%
SPCXSpace Exploration Technologies
$141.98-0.03%

Questions About MYX

What is the current price of Mayne Pharma Group?

Mayne Pharma Group is trading at A$3.24 per share.

What is the 52-week range for Mayne Pharma Group?

Over the past 52 weeks, Mayne Pharma Group has traded between A$2.04 and A$6.50.

How much debt does Mayne Pharma Group have?

As of the most recent reporting period, Mayne Pharma Group reported total debt of A$41.27M.

How much cash does Mayne Pharma Group have on hand?

Mayne Pharma Group reported A$62.21M in cash and cash equivalents in its most recent financial results.

What is Mayne Pharma Group’s dividend yield?

Mayne Pharma Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services